|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Saskatchewan |
|---|---|
| Information provided by: | University of Saskatchewan |
| ClinicalTrials.gov Identifier: | NCT00440245 |
Purpose
This study will investigate potential differences in how two puffs of salbutamol protects airway smooth muscle from contracting in people with asthma and chronic obstructive pulmonary disease (COPD).
| Condition | Intervention |
|---|---|
|
Asthma COPD |
Drug: salbutamol |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Bronchoprotection of Salbutamol in Asthma and COPD |
| Estimated Enrollment: | 20 |
| Study Start Date: | February 2007 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
salbutamol
There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
|
Drug: salbutamol
200 micrograms salbutamol from MDI
|
In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g. salbutamol), prior to methacholine challenge has been shown to shift the dose response curve to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The extent of β2 receptor agonist bronchoprotection in COPD is unknown.
Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed to be due to changes in airway smooth muscle (e.g. hypertrophy, hyperplasia, contractile apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.
The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Beth Davis, PhD | 306-966-8290 | beth.davis@usask.ca |
| Canada, Saskatchewan | |
| University of Saskatchewan | Recruiting |
| Saskatoon, Saskatchewan, Canada, S7N0W8 | |
| Contact: Beth Davis, PhD 306-966-8291 beth.davis@usask.ca | |
| Principal Investigator: Donald Cockcroft, MD | |
| Principal Investigator: | Donald Cockcroft, MD | University of Saskatchewan |
More Information
| Responsible Party: | Dr. Donald Cockcroft, University of Saskatchewan |
| ClinicalTrials.gov Identifier: | NCT00440245 History of Changes |
| Other Study ID Numbers: | Bio-REB 06-231 |
| Study First Received: | February 22, 2007 |
| Last Updated: | September 15, 2011 |
| Health Authority: | Canada: Health Canada |
|
Asthma Lung Diseases Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Bronchial Diseases Respiratory Tract Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Albuterol Tocolytic Agents Reproductive Control Agents Physiological Effects of Drugs |
Pharmacologic Actions Therapeutic Uses Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents |
